Cargando…
The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients
BACKGROUND: Prostate cancer (PCa) is characterised by great heterogeneity of the disease progression rate. Tumours range from insignificant and not life threatening to high risk for relapse ones. Consequently, a large number of patients undergo unnecessary treatment. miR-145 is a well-documented tum...
Autores principales: | Avgeris, M, Stravodimos, K, Fragoulis, E G, Scorilas, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694240/ https://www.ncbi.nlm.nih.gov/pubmed/23703249 http://dx.doi.org/10.1038/bjc.2013.250 |
Ejemplares similares
-
miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer
por: Chiyomaru, T, et al.
Publicado: (2010) -
The tumour suppressor miR-34c targets MET in prostate cancer cells
por: Hagman, Z, et al.
Publicado: (2013) -
Epigenetic regulation of MIR145 core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome
por: Pilala, Katerina-Marina, et al.
Publicado: (2022) -
Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors
por: Xu, Y, et al.
Publicado: (2012) -
miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215
por: White, N M A, et al.
Publicado: (2011)